Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: Correlation with pathological response grading system based on tumor cellularity

Journal of Computer Assisted Tomography

Volumn 36, Issue 2, 2012, Pages 200-206

  Kim, Tae Hee ^a   Kang, Doo Kyoung ^a   Yim, Hyunee ^b   Jung, Yong Sik ^b   Kim, Ku Sang ^b   Kang, Seok Yun ^b  

^a Ajou University School of Medicine   (South Korea)

^b Department of Pathology ^*  (South Korea)

Author keywords

breast cancer; chemotherapy; MRI; regression; tumor cellularity

Indexed keywords

CHEMOTHERAPY; DISEASES; GRADING; MAGNETIC RESONANCE IMAGING; MAGNETISM; MEDICAL IMAGING; REGRESSION ANALYSIS; RESONANCE; SHRINKAGE;

BREAST CANCER; CANCER PATIENTS; CLASSIFIEDS; GRADING SYSTEM; LESION PATTERNS; NEOADJUVANT CHEMOTHERAPIES; PATHOLOGICAL RESPONSE; REGRESSION; TUMOR CELLULARITY; TUMOR REGRESSION;

TUMORS;

ANTHRACYCLINE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CONTRAST ENHANCEMENT; FEMALE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR SHRINKAGE; TUMOR VOLUME;

EID: 84859203270     PISSN: 03638715     EISSN: 15323145     Source Type: Journal    
DOI: 10.1097/RCT.0b013e318246abf3     Document Type: Article

References (31)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
2. Suzuki C, Jacobsson H, Hatschek T, et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics. 2008;28:329-344.
3. Rieber A, Zeitler H, Rosenthal H, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol. 1997;70:452-458. (Pubitemid 27229264)
4. Wasser K, Sinn HP, Fink C, et al. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol. 2003;13:1213-1223. (Pubitemid 36790621)
5. Bahri S, Chen JH, Mehta RS, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol. 2009;16:1619-1628.
6. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320-327. (Pubitemid 37322062)
7. Tozaki M, Kobayashi T, Uno S, et al. Breast-conserving surgery after chemotherapy: value of MDCT for determining tumor distribution and shrinkage pattern. AJR Am J Roentgenol. 2006;186:431-439. (Pubitemid 46100313)
8. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685. (Pubitemid 28363030)
9. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93-100. (Pubitemid 28041584)
10. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
11. Rouzier R, Extra JM, Carton M, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol. 2001;19:3828-3835. (Pubitemid 32880061)
12. Weatherall PT, Evans GF, Metzger GJ, et al. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging. 2001;13:868-875. (Pubitemid 32479944)
13. Rieber A, Brambs HJ, Gabelmann A, et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol. 2002;12:1711-1719. (Pubitemid 36940255)
14. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002;179:1193-1199. (Pubitemid 35204372)
15. Uematsu T, Kasami M, Yuen S. Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy. Eur Radiol. 2010;20:2315-2322.
16. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol. 2003;181:1275-1282. (Pubitemid 37296403)
17. Rajan R, Poniecka A, Smith TL, et al. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer. 2004;100:1365-1373. (Pubitemid 38366838)
18. Balu-Maestro C, Chapellier C, Bleuse A, et al. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat. 2002;72:145-152. (Pubitemid 34407209)
19. Akazawa K, Tamaki Y, Taguchi T, et al. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy. Breast J. 2006;12:130-137.
20. Lyou CY, Cho N, Kim SM, et al. Computer-aided evaluation of breast MRI for the residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy. Korean J Radiol. 2011;12:34-43.
21. Akazawa K, Tamaki Y, Taguchi T, et al. Potential of reduction in total tumor volume measured with 3D-MRI as a prognostic factor for locally-advanced breast cancer patients treated with primary chemotherapy. Breast J. 2008;14:523-531.
22. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-4174. (Pubitemid 46606185)
23. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-785. (Pubitemid 351264391)
24. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681-695. (Pubitemid 34845919)
25. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 1993;16:223-228. (Pubitemid 23184384)
26. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995;180:297-306.
27. Carey LA, Metzger R, Dees EC, et al. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst. 2005;97:1137-1142. (Pubitemid 41511213)
28. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-4422. (Pubitemid 350013847)
29. Yuan Y, Chen XS, Liu SY, et al. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. AJR Am J Roentgenol. 2010;195:260-268.
30. Akashi-Tanaka S, Fukutomi T, Watanabe T, et al. Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer. 2001;96:66-73. (Pubitemid 32147686)
31. Nicoletto MO, Nitti D, Pescarini L, et al. Correlation between magnetic resonance imaging and histopathological tumor response after neoadjuvant chemotherapy in breast cancer. Tumori. 2008;94:481-488.